Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 8.89K shares, a 225.25% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 5.12K shares.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.73K shares, a 96.18% decline from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 71.56K shares.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 11.63K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 8.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 14.01K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 5.12K shares 10-Q · filed 2026-05-12 | 7.86K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 2.73K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 6.35K shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 2.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 47.95K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-15 | |
| 2024-12-31 | 3.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 71.56K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 41.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2021-12-31 | 11.63K shares 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |